RU2012148721A - Композиции и способы для лечения обострения хобл - Google Patents

Композиции и способы для лечения обострения хобл Download PDF

Info

Publication number
RU2012148721A
RU2012148721A RU2012148721/10A RU2012148721A RU2012148721A RU 2012148721 A RU2012148721 A RU 2012148721A RU 2012148721/10 A RU2012148721/10 A RU 2012148721/10A RU 2012148721 A RU2012148721 A RU 2012148721A RU 2012148721 A RU2012148721 A RU 2012148721A
Authority
RU
Russia
Prior art keywords
antibody
copd
patient
exacerbation
inhibits
Prior art date
Application number
RU2012148721/10A
Other languages
English (en)
Russian (ru)
Inventor
Донна ФИНЧ
Энтони КОЙЛ
Мартин СТЭМПФЛИ
Original Assignee
Медиммьюн Лимитед
Макмастер Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммьюн Лимитед, Макмастер Юниверсити filed Critical Медиммьюн Лимитед
Publication of RU2012148721A publication Critical patent/RU2012148721A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2012148721/10A 2010-04-16 2011-04-18 Композиции и способы для лечения обострения хобл RU2012148721A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US61/325,241 2010-04-16
US41610210P 2010-11-22 2010-11-22
US61/416,102 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (1)

Publication Number Publication Date
RU2012148721A true RU2012148721A (ru) 2014-05-27

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012148721/10A RU2012148721A (ru) 2010-04-16 2011-04-18 Композиции и способы для лечения обострения хобл

Country Status (11)

Country Link
US (1) US20130149312A1 (enExample)
EP (1) EP2558112A4 (enExample)
JP (1) JP2013525310A (enExample)
KR (1) KR20130086141A (enExample)
CN (1) CN102985100A (enExample)
AU (1) AU2011239402A1 (enExample)
BR (1) BR112012026545A2 (enExample)
CA (1) CA2796083A1 (enExample)
MX (1) MX2012012063A (enExample)
RU (1) RU2012148721A (enExample)
WO (1) WO2011130745A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
JPWO2015182121A1 (ja) * 2014-05-29 2017-04-27 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
WO2016168696A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Methods to improve induction of iga antibodies by vaccines
WO2016197087A1 (en) 2015-06-05 2016-12-08 The University Of Rochester Shape-memory polymers and methods of making and use thereof
KR102208549B1 (ko) * 2019-05-16 2021-01-27 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
JP2023529764A (ja) * 2019-12-02 2023-07-12 アルタバント・サイエンシズ・ゲーエムベーハー 下気道障害の処置
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003765A1 (en) * 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Also Published As

Publication number Publication date
CA2796083A1 (en) 2011-10-20
BR112012026545A2 (pt) 2019-09-24
AU2011239402A1 (en) 2012-10-25
EP2558112A4 (en) 2014-06-18
US20130149312A1 (en) 2013-06-13
WO2011130745A1 (en) 2011-10-20
KR20130086141A (ko) 2013-07-31
EP2558112A1 (en) 2013-02-20
CN102985100A (zh) 2013-03-20
MX2012012063A (es) 2013-03-21
JP2013525310A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
Cruz-Teran et al. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
Shen et al. The interaction between pulmonary fibrosis and COVID-19 and the application of related anti-fibrotic drugs
KR20230005139A (ko) 코로나바이러스 감염 및 이로 인한 염증-유발된 폐 손상의 치료 방법
JP2023515271A5 (enExample)
JP2013525310A5 (enExample)
NZ567441A (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases.
JP2017507139A5 (enExample)
RU2017115845A (ru) Игаляционное устройство для использования в аэрозольной терапии респираторных заболеваний
JP2006522830A5 (enExample)
JP2022163050A (ja) 院内肺炎を予防または治療する方法
MX2012012063A (es) Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd).
US20220363746A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
JP2020504135A5 (enExample)
Kurihara et al. Thymic stromal lymphopoietin contributes to ozone-induced exacerbations of eosinophilic airway inflammation via granulocyte colony-stimulating factor in mice
JP2007506681A5 (enExample)
RU2017110093A (ru) Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса
Budhiraja et al. The management of acute bronchiolitis in infants
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
Sangkham et al. Estimated burden of disease and health effects attributable to fine particulate matter and ozone exposure in relation to COPD and cardiovascular disease in Upper Northern Thailand
CN108339118A (zh) 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
TW202423978A (zh) 急性呼吸衰竭之治療
US12583929B2 (en) Method of treating acute respiratory distress syndrome
WO2022192093A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US10899829B2 (en) Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
JP2023521909A (ja) 呼吸器疾患の治療

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150916